These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 29386483)

  • 1. Exploration of the Key Factors for Optimizing the in Vivo Oral Delivery of Insulin by Using a Noncovalent Strategy with Cell-Penetrating Peptides.
    Kamei N; Shigei C; Hasegawa R; Takeda-Morishita M
    Biol Pharm Bull; 2018; 41(2):239-246. PubMed ID: 29386483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo proof of concept of oral insulin delivery based on a co-administration strategy with the cell-penetrating peptide penetratin.
    Nielsen EJ; Yoshida S; Kamei N; Iwamae R; Khafagy el-S; Olsen J; Rahbek UL; Pedersen BL; Takayama K; Takeda-Morishita M
    J Control Release; 2014 Sep; 189():19-24. PubMed ID: 24973720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Region-Dependent Role of Cell-Penetrating Peptides in Insulin Absorption Across the Rat Small Intestinal Membrane.
    Khafagy el-S; Iwamae R; Kamei N; Takeda-Morishita M
    AAPS J; 2015 Nov; 17(6):1427-37. PubMed ID: 26216471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-month subchronic toxicity study of cell-penetrating peptides for insulin nasal delivery in rats.
    Khafagy el-S; Kamei N; Nielsen EJ; Nishio R; Takeda-Morishita M
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):736-43. PubMed ID: 24060698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of different intestinal conditions on the intermolecular interaction between insulin and cell-penetrating peptide penetratin and on its contribution to stimulation of permeation through intestinal epithelium.
    Kamei N; Aoyama Y; Khafagy el-S; Henmi M; Takeda-Morishita M
    Eur J Pharm Biopharm; 2015 Aug; 94():42-51. PubMed ID: 25960330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dependence of Intestinal Absorption Profile of Insulin on Carrier Morphology Composed of β-Cyclodextrin-Grafted Chitosan.
    Daimon Y; Kamei N; Kawakami K; Takeda-Morishita M; Izawa H; Takechi-Haraya Y; Saito H; Sakai H; Abe M; Ariga K
    Mol Pharm; 2016 Dec; 13(12):4034-4042. PubMed ID: 27749081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Applicability and Limitations of Cell-Penetrating Peptides in Noncovalent Mucosal Drug or Carrier Delivery Systems.
    Kamei N; Bech Nielsen EJ; Nakakubo T; Aoyama Y; Rahbek UL; Pedersen BL; Takeda-Morishita M
    J Pharm Sci; 2016 Feb; 105(2):747-753. PubMed ID: 26869427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of cell-penetrating peptides to improve intestinal insulin absorption.
    Kamei N; Morishita M; Eda Y; Ida N; Nishio R; Takayama K
    J Control Release; 2008 Nov; 132(1):21-5. PubMed ID: 18727945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of a non-covalent cell-penetrating peptide strategy to enhance the nasal delivery of interferon beta and its PEGylated form.
    Iwase Y; Kamei N; Khafagy el-S; Miyamoto M; Takeda-Morishita M
    Int J Pharm; 2016 Aug; 510(1):304-10. PubMed ID: 27343364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular imaging analysis of intestinal insulin absorption boosted by cell-penetrating peptides by using positron emission tomography.
    Kamei N; Morishita M; Kanayama Y; Hasegawa K; Nishimura M; Hayashinaka E; Wada Y; Watanabe Y; Takayama K
    J Control Release; 2010 Aug; 146(1):16-22. PubMed ID: 20457194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain delivery of insulin boosted by intranasal coadministration with cell-penetrating peptides.
    Kamei N; Takeda-Morishita M
    J Control Release; 2015 Jan; 197():105-10. PubMed ID: 25445695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noncovalent Strategy with Cell-Penetrating Peptides to Facilitate the Brain Delivery of Insulin through the Blood-Brain Barrier.
    Kamei N; Yamaoka A; Fukuyama Y; Itokazu R; Takeda-Morishita M
    Biol Pharm Bull; 2018; 41(4):546-554. PubMed ID: 29607927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of cell-penetrating peptides on the nasal absorption of insulin.
    Khafagy el-S; Morishita M; Isowa K; Imai J; Takayama K
    J Control Release; 2009 Jan; 133(2):103-8. PubMed ID: 18930084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral biodrug delivery using cell-penetrating peptide.
    Khafagy el-S; Morishita M
    Adv Drug Deliv Rev; 2012 May; 64(6):531-9. PubMed ID: 22245080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of intestinal luminal contents and the importance of microfold cells on the ability of cell-penetrating peptides to enhance epithelial permeation of insulin.
    Kamei N; Kawano S; Abe R; Hirano S; Ogino H; Tamiwa H; Takeda-Morishita M
    Eur J Pharm Biopharm; 2020 Oct; 155():77-87. PubMed ID: 32781024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of the cell-penetrating peptide penetratin as an oral absorption enhancer.
    Nielsen EJ; Kamei N; Takeda-Morishita M
    Biol Pharm Bull; 2015; 38(1):144-6. PubMed ID: 25744470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Penetratin derivative-based nanocomplexes for enhanced intestinal insulin delivery.
    Zhu X; Shan W; Zhang P; Jin Y; Guan S; Fan T; Yang Y; Zhou Z; Huang Y
    Mol Pharm; 2014 Jan; 11(1):317-28. PubMed ID: 24255985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Noninvasive insulin delivery: the great potential of cell-penetrating peptides.
    Kamei N; Nielsen EJ; Khafagy el-S; Takeda-Morishita M
    Ther Deliv; 2013 Mar; 4(3):315-26. PubMed ID: 23442079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination Strategy with Complexation Hydrogels and Cell-Penetrating Peptides for Oral Delivery of Insulin.
    Fukuoka Y; Khafagy ES; Goto T; Kamei N; Takayama K; Peppas NA; Takeda-Morishita M
    Biol Pharm Bull; 2018; 41(5):811-814. PubMed ID: 29709919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Visualization and Quantitative Assessment of the Brain Distribution of Insulin through Nose-to-Brain Delivery Based on the Cell-Penetrating Peptide Noncovalent Strategy.
    Kamei N; Shingaki T; Kanayama Y; Tanaka M; Zochi R; Hasegawa K; Watanabe Y; Takeda-Morishita M
    Mol Pharm; 2016 Mar; 13(3):1004-11. PubMed ID: 26795701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.